Back
The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
I - Interstitial/parenchymal lung disease
I.a
Pneumonitis (ILD)
I.b
Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.e
Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.f
Acute fibrinous organizing pneumonia (AFOP)
I.i
Subclinical pulmonary infiltrates/ILD
I.m
Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.n
ILD with a granulomatous component
I.q
Fatal pneumonitis (ILD)
I.w
Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence
I.z
Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.ae
Radiation recall pneumonitis
II - Pulmonary edema - Acute lung injury - ARDS
III - Pulmonary/alveolar./airway hemorrhage/bleeding
IV - Airway involvement
V - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VI - Pleural and/or pericardial involvement
VII - Pulmonary vasculopathy
XVI - Imaging
XIX - Pathology
XIX.a
Path: NSIP-cellular pattern (see also Ia, Ib)
XIX.d
Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XIX.e
Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XIX.f
Path: ILD with a granulomatous component (see also Im)
XIX.r
Path: Alveolar hemorrhage (see also IIIa)